Sionna Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Sionna Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has a cash flow conversion efficiency ratio of -0.054x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.63 Million) by net assets ($306.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sionna Therapeutics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Sionna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SION live share price for real-time trading data and today's change.
Sionna Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Sionna Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sionna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see SION market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InfoBeans Technologies Limited
NSE:INFOBEAN
|
0.127x |
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
-0.031x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.055x |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
-0.557x |
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
1.103x |
|
Dae Young Pkg
KO:014160
|
-0.015x |
|
Omiris AG
F:HBD1
|
N/A |
|
American Battery Technology Company Common Stock
NASDAQ:ABAT
|
-0.082x |
Annual Cash Flow Conversion Efficiency for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. Review financial agility of Sionna Therapeutics, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $306.83 Million | $-66.30 Million | -0.216x | -167.01% |
| 2024-12-31 | $-163.71 Million | $-52.79 Million | 0.322x | -15.23% |
| 2023-12-31 | $-114.88 Million | $-43.70 Million | 0.380x | -26.26% |
| 2022-12-31 | $-69.92 Million | $-36.07 Million | 0.516x | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more